TW200800974A - Glucuronate salt of a piperazine compound - Google Patents

Glucuronate salt of a piperazine compound

Info

Publication number
TW200800974A
TW200800974A TW095133454A TW95133454A TW200800974A TW 200800974 A TW200800974 A TW 200800974A TW 095133454 A TW095133454 A TW 095133454A TW 95133454 A TW95133454 A TW 95133454A TW 200800974 A TW200800974 A TW 200800974A
Authority
TW
Taiwan
Prior art keywords
piperazine compound
glucuronate salt
salt form
present
salt
Prior art date
Application number
TW095133454A
Other languages
English (en)
Inventor
Subodh S Deshmukh
Kadum Ali
Christopher R Diorio
Eric C Ehrnsperger
Mahdi B Fawzi
Syed Muzafar Shah
Mahmoud Mirmehrabi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37603202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200800974(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200800974A publication Critical patent/TW200800974A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095133454A 2005-09-12 2006-09-11 Glucuronate salt of a piperazine compound TW200800974A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71616705P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
TW200800974A true TW200800974A (en) 2008-01-01

Family

ID=37603202

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095133454A TW200800974A (en) 2005-09-12 2006-09-11 Glucuronate salt of a piperazine compound

Country Status (20)

Country Link
US (1) US7595310B2 (zh)
EP (1) EP1940830A1 (zh)
JP (1) JP2009507921A (zh)
KR (1) KR20080045285A (zh)
CN (1) CN101287730B (zh)
AR (1) AR056506A1 (zh)
AU (1) AU2006291058B2 (zh)
BR (1) BRPI0615853A2 (zh)
CA (1) CA2620755A1 (zh)
EA (1) EA014942B1 (zh)
GT (1) GT200600414A (zh)
IL (1) IL189809A0 (zh)
MY (1) MY144782A (zh)
NO (1) NO20081809L (zh)
PE (1) PE20070433A1 (zh)
SA (1) SA06270329B1 (zh)
TW (1) TW200800974A (zh)
UA (1) UA95922C2 (zh)
WO (1) WO2007033191A1 (zh)
ZA (1) ZA200802310B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
AR055424A1 (es) 2005-09-12 2007-08-22 Wyeth Corp Formulacion de liberacion sostenida y usos de la misma
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
EA017732B1 (ru) * 2007-05-11 2013-02-28 Рихтер Гедеон Нирт. Сольватная и кристаллическая формы гидрохлорида транс-1{4-[2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил]циклогексил}-3,3-диметилмочевины, способы их получения и их применение в фармацевтических композициях и способах лечения состояний, для которых необходима модуляция дофаминовых рецепторов
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
MY156288A (en) 2008-07-16 2016-01-29 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands.
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4687772A (en) * 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US5162375A (en) * 1988-05-06 1992-11-10 Beecham Group P.L.C. Treatment of neuronal degeneration with 5HT1A agonists
DE4135551A1 (de) 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
US5716960A (en) * 1995-01-13 1998-02-10 U.S. Bioscience Inc. And Individuals Crystalline trimetrexate salts and the process for making the same
SE9900190D0 (sv) 1999-01-22 1999-01-22 Astra Ab New compounds
DE19730989A1 (de) * 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
HU225101B1 (en) * 1997-07-25 2006-06-28 Lundbeck & Co As H Indole and 2,3-dihydroindole derivatives, their preparation, use, and pharmaceutical compositions containing them
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
EP1212320B1 (en) * 1999-08-23 2005-07-06 Solvay Pharmaceuticals B.V. Phenylpiperazines as serotonin reuptake inhibitors
MXPA02007095A (es) 2000-01-19 2003-04-14 Akzo Nobel Nv Combinacion de farmacos para el tratamiento de la depresion y desordenes relacionados que comprenden mirtazapina.
AR032712A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
JP2007502287A (ja) * 2003-08-13 2007-02-08 アムジェン インコーポレイテッド メラニン凝集ホルモン受容体アンタゴニスト
US20050197347A1 (en) 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
AR055424A1 (es) 2005-09-12 2007-08-22 Wyeth Corp Formulacion de liberacion sostenida y usos de la misma
GT200600416A (es) * 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina

Also Published As

Publication number Publication date
MY144782A (en) 2011-11-15
EA014942B1 (ru) 2011-04-29
CA2620755A1 (en) 2007-03-22
JP2009507921A (ja) 2009-02-26
US7595310B2 (en) 2009-09-29
ZA200802310B (en) 2008-12-31
AU2006291058A1 (en) 2007-03-22
GT200600414A (es) 2007-09-20
KR20080045285A (ko) 2008-05-22
WO2007033191A1 (en) 2007-03-22
CN101287730B (zh) 2012-03-07
EP1940830A1 (en) 2008-07-09
UA95922C2 (en) 2011-09-26
NO20081809L (no) 2008-04-14
IL189809A0 (en) 2008-08-07
BRPI0615853A2 (pt) 2011-05-31
SA06270329B1 (ar) 2010-06-15
PE20070433A1 (es) 2007-04-24
CN101287730A (zh) 2008-10-15
EA200800810A1 (ru) 2008-10-30
AR056506A1 (es) 2007-10-10
AU2006291058B2 (en) 2011-09-08
US20070254876A1 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
TW200800974A (en) Glucuronate salt of a piperazine compound
MY140740A (en) Resin compositions
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
UA94833C2 (en) Substituted bicyclolactams
AU2003228770A1 (en) Substituted pyrazolopyrimidines
BR0305767A (pt) Métodos e composições para a preparação de derivados de ácido 4-substituìdo 3-hidroxibutìrico
MX2010001576A (es) Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6).
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
MXPA02011370A (es) Iminoazinas substituidas.
UA106191C2 (ru) Способ получения транс-1-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-3,3-диметилпиперазина
MX2009004343A (es) Compuestos organicos.
MX2009008324A (es) Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6.
WO2008147812A3 (en) 4' substituted compounds having 5-ht6 receptor affinity
MX2023009045A (es) Derivados novedosos de pirimidin-2-il sulfonamida.
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
TW200720233A (en) Hydroxynaphthalenedicarboxylic acid hydrazide dimer and derivatives thereof as well as process for preparing them
MX2011008324A (es) Composiciones que contienen 1,2-benzisotiazolin-3-ona.
EP1845780A4 (en) USES OF METHYLPHENIDATE DERIVATIVES
AR057555A1 (es) Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
TW200720234A (en) Hydroxynaphthalenedicarboxylic acid hydrazide and derivatives thereof as well as process for preparing them
WO2006079720A8 (fr) Nouveaux derives d1oximes heterocycliques, leur procede de preparation et leur utilisation comme agents hypoglycemiants et hypoli pemiants
TW200600013A (en) 5,6-Dialkyl-7-aminotriazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds
DE602006013828D1 (en) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
BR0308601A (pt) inibidores de carboxipeptidase b de plasma